Motor fluctuations (MF) are deemed by patients with Parkinson's disease (PD) as the most
troublesome disease feature resulting from the increasing impairment in responsiveness to …

Background: In advanced Parkinson's disease (PD), dyskinesias and non-motor symptoms
such as sleep dysfunction can significantly impair quality of life, and high-quality …

Background While immediate benefits of levodopa–carbidopa intestinal gel (LCIG) are
evident in patients with Parkinson's disease (PD), long-term LCIG effects require further …

Background: Gait issues, including reduced speed, stride length and freezing of gait (FoG),
are disabling in advanced phases of Parkinson's disease (PD), and their treatment is …

Background and Objectives: Currently, no tool exists to predict clinical outcomes in patients
with advanced Parkinson's disease (PD) under levodopa–carbidopa intestinal gel (LCIG) …

Objective: Although Levodopa-carbidopa intestinal gel (LCIG) treatment has shown to be
efficacious in motor and some non-motor symptoms (NMS), not all the patients with …

We read with interest the report by Mulroy et al about the patient with Parkinson's disease
(PD) who developed troublesome dyskinesias while on levodopa carbidopa intestinal gel …

We thank the authors for their interest in our case, 1 and for sharing their experience of
subthalamic nucleus (STN) deep brain stimulation (DBS) in the treatment of levodopa …

(Figure 1A), generally considered a sufficient on-state therapeutic level. However, LID did
not decrease. Next, considering the possibility that dyskinesia appeared at the peak dose …